Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CODEX DNA, INC.

(DNAY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Codex DNA, Inc. Announces Departure of Timothy E. Cloutier as Senior Vice President, Effective September 17, 2021

09/16/2021 | 05:03pm EDT

Codex DNA, Inc. and Timothy E. Cloutier have entered into an agreement (the Separation Agreement) pursuant to which Mr. Cloutier will depart the Company on September 17, 2021. Under the Separation Agreement, Mr. Cloutier will be entitled to various severance benefits previously approved by the Company’s Board of Directors for employees at the Senior Vice President level in the Company. Mr. Cloutier’s receipt of the Severance Benefits was subject to his execution of the Separation Agreement, which contains, among other provisions, a general release and waiver of claims. Mr. Cloutier’s departure was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.


ę S&P Capital IQ 2021
All news about CODEX DNA, INC.
09/20CODEX DNA, INC.(NASDAQGS : DNAY) added to S&P TMI Index
CI
09/16CODEX DNA : Departure of Directors or Certain Officers; Election of Directors; Appointment..
PU
09/16CODEX DNA, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
09/16Codex DNA, Inc. Announces Departure of Timothy E. Cloutier as Senior Vice President, Ef..
CI
09/01Codex Dna Releases Full-Length Synthetic Genome for Highly Infectious Sars-Cov-2 Delta ..
CI
08/11CODEX DNA : Management's discussion and analysis of financial condition and results of ope..
AQ
08/10CODEX DNA : Reports Second Quarter 2021 Financial Results (Form 8-K)
PU
08/10CODEX DNA, INC. : Results of Operations and Financial Condition, Financial Statements and ..
AQ
08/10CODEX DNA : Earnings Flash (DNAY) CODEX DNA Reports Q2 Revenue $2.9M, vs. Street Est of $2..
MT
08/10CODEX DNA : Reports Second Quarter 2021 Financial Results
AQ
More news
Analyst Recommendations on CODEX DNA, INC.
More recommendations
Financials (USD)
Sales 2021 12,5 M - -
Net income 2021 -32,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -7,55x
Yield 2021 -
Capitalization 268 M 268 M -
Capi. / Sales 2021 21,4x
Capi. / Sales 2022 13,0x
Nbr of Employees 108
Free-Float 47,3%
Chart CODEX DNA, INC.
Duration : Period :
Codex DNA, Inc. Technical Analysis Chart | DNAY | US1920031010 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 9,14 $
Average target price 26,50 $
Spread / Average Target 190%
EPS Revisions
Managers and Directors
Todd R. Nelson President, Chief Executive Officer & Director
Jennifer Isacoff McNealey Chief Financial Officer
Daniel G. Gibson Chief Technology Officer
Justin O. Emory Vice President-Information Technology
Franklin R. Witney Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CODEX DNA, INC.0.00%268
THERMO FISHER SCIENTIFIC31.38%240 757
DANAHER CORPORATION41.07%223 934
INTUITIVE SURGICAL, INC.26.00%122 004
SIEMENS HEALTHINEERS AG42.35%77 031
EDWARDS LIFESCIENCES CORPORATION27.80%72 674